HM Payson & Co. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 252 shares of the biopharmaceutical company’s stock, valued at approximately $59,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $41,529,000. Los Angeles Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the period. Truist Financial Corp lifted its stake in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after buying an additional 2,539 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after buying an additional 8,462 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the transaction, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,986 shares of company stock worth $20,397,849. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ:ALNY opened at $244.52 on Monday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business has a 50 day moving average of $254.70 and a 200-day moving average of $261.25. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market cap of $31.65 billion, a PE ratio of -112.68 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ALNY. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Sanford C. Bernstein lowered their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $304.26.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.